Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Special issue explores how evolution can help doctors understand and treat diseases

What does evolution - a field that often deals with changes over many generations - have to do with preventing and treating disease in our lifetime?

28 Jan 2010

Sinovac prices public offering at $5.75 per common share

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today that it has priced its public offering of 10,000,000 common shares at $5.75 per common share. Sinovac has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,500,000 common shares on the same terms and conditions.

28 Jan 2010

NIH awards GE Global Research $3.27M to develop highly mobile, less costly MRI systems

Working to expand access of state-of-the-art medical imaging to underdeveloped regions around the world, GE Global Research, the technology development arm for the General Electric Company, has been awarded a four-year, $3.27 million award from National Institutes of Health (NIH) to develop new magnet technology that will make MRI systems less costly and easier to site.

28 Jan 2010

Gold Bond Ultimate Hand Sanitizer Moisturizer now available in market

Love your hand sanitizer – but hate how it dries out your skin? Now, Gold Bond®, the trusted name in skin care for more than 100 years, has launched Gold Bond Ultimate® Hand Sanitizer Moisturizer, a true two-in-one product created to effectively kill germs but not your hands.

28 Jan 2010

Inovio Biomedical unveils new clinical-grade, miniaturized electroporation device

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, today unveiled its new clinical-grade, miniaturized electroporation device designed to be an easy-to-use, portable delivery product for DNA vaccines.

28 Jan 2010

NIH to perform exploratory studies on ImmuneRegen BioSciences' Homspera

ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced the execution of an agreement with the National Institute of Health (NIH) / National Cancer Institute (NCI) to commence studies utilizing ImmuneRegen's Homspera.

28 Jan 2010

NewsRx publishes new encyclopedia on vaccines

NewsRx, a 25-year-old publisher and international news organization headquartered in Atlanta, has published a new encyclopedia on vaccines -- Encyclopedia of Vaccines, 2009: An encyK Resource for Parents, Patients & Professionals.

28 Jan 2010

Budgetary freeze will impact over 5M Americans afflicted with chronic viral hepatitis

Ms. Lorren Sandt, Chair of the National Viral Hepatitis Roundtable (NVHR) issued the following statement in advance of the President's State of the Union Address. NVHR is a coalition of more than 150 public, private, and voluntary organizations dedicated to reducing the incidence of infection, morbidity, and mortality from chronic viral hepatitis that afflicts more than 5 million Americans:

28 Jan 2010

African vaccine maker plans to increase production capacity sevenfold by 2013

Biovac Institute, a South African vaccine maker, said Monday that it is working with other major pharmaceutical firms to increase its annual capacity sevenfold to 35 million doses by 2013, Reuters reports.

28 Jan 2010

Good bacteria may help counteract negative effects of antibiotics in humans

Scientists have long pondered the seeming contradiction that taking broad-spectrum antibiotics over a long period of time can lead to severe secondary bacterial infections. Now researchers from the University of Pennsylvania School of Medicine may have figured out why.

27 Jan 2010

WHO addresses handling of H1N1 at Council of Europe meeting

During a Council of Europe meeting on Tuesday to address the WHO's handling of the H1N1 virus, the WHO said it had not "fallen under the sway of drugs firms and exaggerated the dangers of the H1N1 flu virus, but said it might have handled the crisis better," Reuters reports.

27 Jan 2010

Juvaris BioTherapeutics completes second close on its Series B equity financing

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed a second close on its Series B equity financing of up to $25 million. The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.

27 Jan 2010

NIST researchers determine best practices for storing and monitoring refrigerated vaccines

Every year, billions of dollars worth of vaccines are shipped to thousands of medical providers across the country, and every year doctors must dispose of tens of millions of dollars worth of those vaccines because they became too warm or too cold while in storage.

27 Jan 2010

Hypothermic machine perfusion outperforms standard cold-storage liver preservation

Preserving organs on ice prior to transplantation, an approach known as cold storage or CS, has been the standard practice in liver transplant for 20 years. Now there is new evidence that a technique called hypothermic machine perfusion (HMP) may offer an improvement, according to the first-ever study comparing the impact of the two techniques on transplant outcomes.

27 Jan 2010

New research project aims at understanding the genetic origins of childhood cancers

St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis, today announced an unprecedented effort to identify the genetic changes that give rise to some of the world's deadliest childhood cancers.

27 Jan 2010

WellPoint announces net income of $2.7 billion for fourth-quarter fiscal 2009

WellPoint, Inc. today announced that fourth quarter 2009 net income was $2.7 billion, or $5.95 per share. The results included net after-tax income of approximately $2.2 billion, or $4.79 per share, resulting from a gain on the sale of the NextRx pharmacy benefit management subsidiaries ("NextRx"), partially offset by costs for restructuring activities and intangible asset impairments.

27 Jan 2010

MBL generates human monoclonal antibodies against pandemic A type influenza virus

Medical & Biological Laboratories Co., Ltd. (MBL), with the collaboration of Osaka University, has successfully generated several fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza virus by utilizing blood samples from volunteers who were inoculated with influenza vaccine.

27 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Massachusetts Department of Public Health grants WDL to Pharmarama

Pharmarama, a leader in the strategic sourcing of comparator drugs for global clinical trials, today announced that the Massachusetts Department of Public Health has granted the company a Wholesale Distributor’s License (WDL). The license enables Pharmarama to operate its pharmaceutical cold-chain and ambient storage and distribution facility in suburban Boston to provide extensive sourcing and comparator product storage services for its clients.

27 Jan 2010

Patients with COPD could benefit from treatment with drugs that block sestrin function

Chronic obstructive pulmonary disease (COPD) is defined by emphysema and/or chronic bronchitis. It destroys the normal architecture of the lung and inhibits the mechanical aspects of breathing, which prevents necessary gas exchange. Patients suffer from coughing fits, wheezing, and increased incidence of lung infections.

27 Jan 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Special issue explores how evolution can help doctors understand and treat diseases

Sinovac prices public offering at $5.75 per common share

NIH awards GE Global Research $3.27M to develop highly mobile, less costly MRI systems

Gold Bond Ultimate Hand Sanitizer Moisturizer now available in market

Inovio Biomedical unveils new clinical-grade, miniaturized electroporation device

NIH to perform exploratory studies on ImmuneRegen BioSciences' Homspera

NewsRx publishes new encyclopedia on vaccines

Budgetary freeze will impact over 5M Americans afflicted with chronic viral hepatitis

African vaccine maker plans to increase production capacity sevenfold by 2013

Good bacteria may help counteract negative effects of antibiotics in humans

WHO addresses handling of H1N1 at Council of Europe meeting

Juvaris BioTherapeutics completes second close on its Series B equity financing

NIST researchers determine best practices for storing and monitoring refrigerated vaccines

Hypothermic machine perfusion outperforms standard cold-storage liver preservation

New research project aims at understanding the genetic origins of childhood cancers

WellPoint announces net income of $2.7 billion for fourth-quarter fiscal 2009

MBL generates human monoclonal antibodies against pandemic A type influenza virus

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Massachusetts Department of Public Health grants WDL to Pharmarama

Patients with COPD could benefit from treatment with drugs that block sestrin function

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Modular cleanrooms: Enhancing flexibility and compliance

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Modular cleanrooms: Enhancing flexibility and compliance

Newsletters you may be interested in